Robert Williams - Viracta Therapeutics CoFounder

VIRX Stock  USD 0.18  0.01  5.88%   

Insider

Robert Williams is CoFounder of Viracta Therapeutics
Age 69
Address 2533 South Coast Highway 101, Cardiff, CA, United States, 92007
Phone858 400 8470
Webhttps://www.viracta.com

Viracta Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.572) % which means that it has lost $0.572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0867) %, meaning that it created substantial loss on money invested by shareholders. Viracta Therapeutics' management efficiency ratios could be used to measure how well Viracta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.95 in 2024. Return On Capital Employed is likely to drop to -2.91 in 2024. At this time, Viracta Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.6 M in 2024, whereas Total Assets are likely to drop slightly above 54.4 M in 2024.
Viracta Therapeutics currently holds 25.56 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Viracta Therapeutics has a current ratio of 11.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Viracta Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Christopher GallettaTrevi Therapeutics
46
Jennifer LeonardEyepoint Pharmaceuticals
N/A
Mark VignolaTerns Pharmaceuticals
46
CBE FMedsciBicycle Therapeutics
71
Franco ValleBiomea Fusion
43
Gillian LangfordBicycle Therapeutics
N/A
MBA MBABicycle Therapeutics
43
John MDVincerx Pharma
N/A
Sheng DingTenaya Therapeutics
N/A
Henric BjarkeInozyme Pharma
57
John CastleMonte Rosa Therapeutics
53
Silvia BuonamiciMonte Rosa Therapeutics
N/A
Benoit BruneauTenaya Therapeutics
N/A
George ElstonEyepoint Pharmaceuticals
59
Arthur TaverasX4 Pharmaceuticals
60
Jennifer GoodTrevi Therapeutics
59
Jennifer ChampouxMonte Rosa Therapeutics
N/A
Christine CPAMereo BioPharma Group
43
Ajim CFAMonte Rosa Therapeutics
47
Dr RobertsLyra Therapeutics
56
Owen WallaceMonte Rosa Therapeutics
55
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. Viracta Therapeutics (VIRX) is traded on NASDAQ Exchange in USA. It is located in 2533 South Coast Highway 101, Cardiff, CA, United States, 92007 and employs 40 people. Viracta Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Viracta Therapeutics Leadership Team

Elected by the shareholders, the Viracta Therapeutics' board of directors comprises two types of representatives: Viracta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viracta. The board's role is to monitor Viracta Therapeutics' management team and ensure that shareholders' interests are well served. Viracta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viracta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel CPA, COO, CFO
Cheryl Madsen, Senior Affairs
Daniel Chevallard, COO CFO
Thalia MD, CoFounder
Patric MBA, Senior Strategy
Ronald MD, CoFounder Consultant
George Hillman, CoFounder
Robert Williams, CoFounder
Robert McRae, Vice Alliances
Ayman ElGuindy, Chief Officer
Mark Rothera, President CEO
Stewart Brown, Senior Counsel
Susan MD, Scientific Consultant
Michael Faerm, Chief Officer
Lisa Rojkjaer, Chief Officer
Biljana PharmD, Senior Development

Viracta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viracta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.